Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination
with sunitinib. This is a multi-part study that will enroll approximately 426 patients. Part
1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to
be used in subsequent parts in approximately 20 patients who have received at least one prior
line of therapy for GIST and 2) evaluating for drug-drug interactions between CGT9486 and
sunitinib in approximately 18 patients who have received at least two prior tyrosine kinase
inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388
patients who are intolerant to, or who failed prior treatment with imatinib only and will
compare the efficacy of CGT9486 plus sunitinib to sunitinib alone with patients being
randomized in a 1:1 manner.
Phase III
Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics
CGT9486 (PLX9486), SU011248 (Sunitinib), Sunitinib
Davis, Elizabeth
Vanderbilt University


18 Years
Inclusion Criteria:

Histologically confirmed locally advanced, metastatic, and/or unresectable GIST. Molecular pathology report must be available for Part 2; if molecular pathology report is unavailable or inadequate, an archival or fresh tumor tissue sample will be required to evaluate mutational status prior to randomization.

Documented disease progression on or intolerance to imatinib

Subjects must have received the following treatment:

Part 1a: Treatment with 1 prior lines of therapy for GIST

Part 1b: Treatment with 2 prior TKI for GISTs

Part 2: Prior treatment with imatinib only

Have at least 1 measurable lesion according to mRECIST v1.1

ECOG - 0 to 2

Have clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits

Exclusion Criteria:

Known PDGFR driving mutations or known succinate dehydrogenase deficiency

Clinically significant cardiac disease

Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug

Gastrointestinal abnormalities including, but not limited to, significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption

Any active bleeding excluding hemorrhoidal or gum bleeding

Seropositive for HIV 1 or 2, or positive for hepatitis B surface antigen or hepatitis C virus (HCV) antibody.

Active, uncontrolled, systemic bacterial, fungal, or viral infections at Screening

Received strong CYP3A4 inhibitors or inducers

Received sunitinib within 3 weeks (Part 1a, Part 1b)

To learn more about any of our clinical
trials, call 615-936-8422.